Who are Oxaliplatin intra-arteriel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eloxatin, carboplatin periocular injection, Carboplatin Injection, Oxaliplatin (OXAL), Carboplatin or Cisplatin, Oxaliplatin injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oxaliplatin-intra-arteriel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Oxaliplatin intra-arteriel — Competitive Intelligence Brief

Oxaliplatin intra-arteriel (Oxaliplatin intra-arteriel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based chemotherapy agent. Area: Oncology.

phase 3 Platinum-based chemotherapy agent DNA (forms crosslinks) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Oxaliplatin intra-arteriel (Oxaliplatin intra-arteriel) — Federation Francophone de Cancerologie Digestive. Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill cancer cells, delivered directly into the hepatic artery to maximize local concentration in liver tumors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oxaliplatin intra-arteriel TARGET	Oxaliplatin intra-arteriel	Federation Francophone de Cancerologie Digestive	phase 3	Platinum-based chemotherapy agent	DNA (forms crosslinks)
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
carboplatin periocular injection	carboplatin periocular injection	Sun Yat-sen University	marketed	Platinum-based chemotherapy agent	DNA
Carboplatin Injection	Carboplatin Injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	Platinum-based chemotherapy agent	DNA
Oxaliplatin (OXAL)	Oxaliplatin (OXAL)	Memorial Sloan Kettering Cancer Center	marketed	Platinum-based chemotherapy agent	DNA
Carboplatin or Cisplatin	Carboplatin or Cisplatin	Second Hospital of Shanxi Medical University	marketed	Platinum-based chemotherapy agent	DNA
Oxaliplatin injection	Oxaliplatin injection	Akeso	phase 3	Platinum-based chemotherapy agent	DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platinum-based chemotherapy agent class)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 3 drugs in this class
Merck Sharp & Dohme LLC · 2 drugs in this class
Federation Francophone de Cancerologie Digestive · 2 drugs in this class
Sun Yat-sen University · 2 drugs in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Chinese Academy of Medical Sciences · 1 drug in this class
Biocad · 1 drug in this class
Gruppo Oncologico Italiano di Ricerca Clinica · 1 drug in this class
Celgene · 1 drug in this class
Gao-jun Teng · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oxaliplatin intra-arteriel — Competitive Intelligence Brief. https://druglandscape.com/ci/oxaliplatin-intra-arteriel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab